Recombinant Human UDP-glucuronosyltransferase 2B17 (UGT2B17), partial

1. These data can be used to predict variability in the metabolism of UGT2B17 substrates. PMID: 29602798
2. UGT2B17 was deleted in 64% of children with lymphoblastic malignancy, but in 83% of children with non-lymphoblastic malignancy. UGT2B17 deletion polymorphism may improve the relapse-free rate in children with non-lymphoblastic malignancy. PMID: 27805301
3. Study provides the first evidence of null genotype involvement in UGT2B17 as a risk factor for benign prostatic hyperplasia. PMID: 28882566
4. Chronic lymphocytic leukemia patients with high UGT2B17 and LPL expression have significantly reduced survival. PMID: 26589911
5. UGT2B17 contributes to the in-vitro glucuronidation of arctigenin in liver/intestinal microsomes. PMID: 26407805
6. GC-C-IRMS analysis sensitive to testosterone doping independent of UGT2B17 genotype. PMID: 26198073
7. UGT2B17 mismatch has a negative clinical impact in allogeneic HSCT from HLA-identical sibling donors only when a male donor is used. PMID: 26367234
8. This descriptive study examines correlations between concentrations of tamoxifen's glucuronide metabolites and genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 in 132 patients with estrogen receptor-positive breast cancer under treatment with tamoxifen. PMID: 26176234
9. UGT2B17 deletion polymorphisms are associated with the risk of developing pancreatic cancer in Chinese Han population, especially in the female population. PMID: 26882814
10. UGT2B17-deletion interacting with p16 (+) may modify effects of smoking on TP53-mutations and may further interact with the disruptive TP53-mutations to raise relapse rates among Japanese patients with head and neck squamous cell carcinomas. PMID: 25886176
11. These data suggest that UGT2B17 deletion leads to reduced UGT2B17 activity, and lower BMI in male individuals. This is consistent with the hypothesis that reduced UGT2B17-mediated testosterone excretion results in higher testosterone levels PMID: 25794161
12. The UGT2B17 deletion polymorphism is not associated with tumor risks. PMID: 24802609
13. Structural variants unique to the malignant cell line inactivated: UGT2B17, a gene that inactivates dihydrotestosterone, a known activator of prostate cancer progression. PMID: 23792589
14. Variation in 3HC glucuronidation activity by CYP2A6 caused by UGT2B17 gene deletions did not significantly alter nicotine metabolite ratio in smokers. PMID: 23936477
15. UGT2B17 is a possible target for androgen deprivation therapy of prostate cancer. PMID: 24121496
16. Study indicates that UGT2B17 is not a crucial factor in lung carcinogenesis among Caucasians and shows the importance of investigating such markers in large cohorts from different populations. PMID: 23850147
17. association of the UGT2B17 CNV with AS is particularly interesting given the recent association of this CNV with osteoporosis and the proposed function as it encodes a key enzyme that inhibits androgens PMID: 23927372
18. The prevalence of the UGT2B17 deletion genotype is extremely high in Japanese subjects. PMID: 22887913
19. We observed a significant association between UGT2B17 expressing recipients and UGT2B17 deficient donors with the severity of Acute graft versus host disease. PMID: 22726315
20. The androgen receptor assay may serve as a complement to the urinary testosterone/epitestosterone (T/E) doping test, because this is profoundly influenced by the UGT2B17 deletion polymorphism. PMID: 23294483
21. Report UGT2B17 expression in fetal/adult tissues. PMID: 23223495
22. The present study was aimed to investigate the possible association between 19-base pair (bp) deletion polymorphism of the DHFR gene (rs70991108), null genotype of UGT2B17 as well as the expression level of NGX6 with the risk of breast cancer. PMID: 23053953
23. Data from an in vitro supersome/microsome-based assay suggest that the key steroid-metabolizing enzyme UGT2B17 is inhibited by phenolic dietary substances in red wine and therefore may reduce the rate of testosterone glucuronidation in vivo. PMID: 22958586
24. observed an exclusive involvement of the 2B17 isoform within the UGT protein family in poor-risk chronic lymphocytic leukemia PMID: 23169782
25. Genetic variations in the UGT2B17 gene dramatically affect the pharmacokinetics of MK-7246 in healthy subjects. PMID: 22669291
26. The UGT2B17 Del polymorphism may significantly contribute to prostate cancer susceptibility in men. (Meta-analysis) PMID: 21919858
27. UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women PMID: 21614655
28. we found no evidence of an effect of UGT2B17 CNV on osteoporosis risk in elderly Caucasian women. PMID: 20878390
29. Data show that 698 CNPs loci overlap with known disease-associated or pharmacogenetic-related genes such as CFHR3, CFHR1, GSTTI and UGT2B17. PMID: 21677662
30. data suggest that men have a higher amount of UGT2B17 glucuronidation activity then women PMID: 20810538
31. UGT2B17 expression in prostate cancer is regulated by a novel polymorphism in forkhead boxA1 binding site. PMID: 20628005
32. Overexpression of UGT2B17 is associated with endometrial cancer. PMID: 20554747
33. the association of deletion polymorphism in the UGT2B17 gene with the occurrence of renal disorders on chronic exposure to anabolic androgenic steroids PMID: 20429943
34. Observational study of genetic testing. (HuGE Navigator) PMID: 20192879
35. UGT2B17 deletion polymorphism is associated with a reduced rate of NNAL detoxification in vivo and may increase individual susceptibility to tobacco-related cancers. PMID: 16220109
36. The UGT2B17 polymorphism is strongly associated with the bimodal distribution of testosterone excretion and also with the large difference in testosterone excretion between Koreans and Swedes. PMID: 16332934
37. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 is associated with prostate cancer PMID: 16896035
38. The UGT2B17 deletion polymorphism is associated with prostate cancer risk. PMID: 17387331
39. association of the UGT2B17 deletion with increased lung adenocarcinoma in women is consistent with its association with decreased 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation rates in women PMID: 17416778
40. results suggest that the HSD3B1 N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease PMID: 17826523
41. These findings show that the UGT2B17 deletion polymorphism is not associated with prostate cancer risk in Caucasians. PMID: 17935910
42. The UGT2B17 deletion polymorphism does not play a major role in prostate cancer susceptibility as previously indicated. PMID: 18247404
43. UGT2B17 ia a primary androgen-regulated genes and androgen receptor is required for basal expression and androgen-regulated expression. PMID: 18302198
44. Diversity was unusually high, with evidence of balancing selection in Europe. In contrast, diversity was low in East Asia where a single haplotype predominated, suggesting positive selection for the deletion in this part of the world PMID: 18760392
45. Genome-wide copy-number variation identified a susceptibility gene, UGT2B17, for osteoporosis. PMID: 18992858
46. In pubertal boys, a common homozygous deletion in the UGT2B17 gene strongly affected urinary excretion pattern of androgen metabolites but did not influence circulating androgen levels. PMID: 19088161
47. Large testosterone excretion is associated with a deletion polymorphism of the UGT2B17 gene. This polymorphism decreases T/E ratio level. PMID: 19224506
48. Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 PMID: 19572376

Show More

Hide All

HGNC: 12547

OMIM: 601903

KEGG: hsa:7367

STRING: 9606.ENSP00000320401

UniGene: Hs.575083